所有图片(1)
About This Item
经验公式（希尔记法）:
C26H33NO2
CAS号:
分子量:
391.55
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
推荐产品
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 5 mg/mL, clear
储存温度
−20°C
SMILES字符串
C[C@]12C(C[C@@H](OC(C)=O)CC2)=CC[C@]3([H])[C@]1([H])CC[C@@]4(C)[C@@]3([H])CC=C4C5=CC=CN=C5
InChI
1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
InChI key
UVIQSJCZCSLXRZ-UBUQANBQSA-N
基因信息
human ... CYP17A1(1586)
正在寻找类似产品? 访问 产品对比指南
应用
醋酸阿比特龙已被用于研究其抗肿瘤操作的三维微小肿瘤平台。
生化/生理作用
醋酸阿比特龙是阿比特龙的前药，是 CYP17A1 (CYP450c17) 的强效、选择性和口服生物利用度抑制剂，CYP17A1 是催化两个关键系列反应（17α羟化酶和 17，20 裂解酶）在雄激素和雌激素生物合成中导致 DHEA 和雄烯二酮的形成，最终可能被代谢为睾酮。CYP17 是睾丸和肾上腺中雄激素生物合成的关键酶，因此对它的抑制应停止两地雄激素的产生。醋酸阿比特龙用于治疗转移性去势抵抗性前列腺癌。 醋酸阿比特龙在多西他赛治疗后 CRPC（去势抵抗性前列腺癌）患者中具有显著的抗肿瘤活性。对睾丸、肾上腺和前列腺组织中的雄激素生物合成高度必需。
警示用语：
Danger
危险声明
危险分类
Aquatic Chronic 1 - Repr. 1B - STOT RE 2
靶器官
Endocrine system
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
The Microwell-mesh: A high-throughput 3D prostate cancer spheroid and drug-testing platform.
E. O. Mosaad, et al.
Scientific Reports, 8(1) (2018)
Gerhardt Attard et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(23), 3742-3748 (2009-05-28)
It has been postulated that castration-resistant prostate cancer (CRPC) commonly remains hormone dependent. Abiraterone acetate is a potent, selective, and orally available inhibitor of CYP17, the key enzyme in androgen and estrogen biosynthesis. This was a phase I/II study of
Charles J Ryan et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(9), 1481-1488 (2010-02-18)
Abiraterone acetate is a prodrug of abiraterone, a selective inhibitor of CYP17, the enzyme catalyst for two essential steps in androgen biosynthesis. In castration-resistant prostate cancers (CRPCs), extragonadal androgen sources may sustain tumor growth despite a castrate environment. This phase
E David Crawford et al.
The Journal of urology, 194(6), 1537-1547 (2015-07-22)
The availability of newly approved treatment options for metastatic castration resistant prostate cancer is not matched with conclusive data on optimal sequencing strategies and resistance patterns. A comprehensive review of efficacy and safety data for new agents and current knowledge
Daniel C Danila et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(9), 1496-1501 (2010-02-18)
Persistence of ligand-mediated androgen receptor signaling has been documented in castration-resistant prostate cancers (CRPCs). Abiraterone acetate (AA) is a potent and selective inhibitor of CYP17, which is required for androgen biosynthesis in the testes, adrenal glands, and prostate tissue. This
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门